title: Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth.
abstract: BACKGROUND
  The duration of protection after hepatitis B vaccination of infants is unknown.
  
  
  METHODS
  We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine. Those with nonprotective titers (<10 mIU/mL) received a booster dose. We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers.
  
  
  RESULTS
  Of low risk infants receiving a plasma-derived vaccine, 41% (42 of 102) of those whose primary response was unknown and 24% (4 of 17) who had initially responded retained protective titers (> or = 10 mIU/mL) of anti-HBs at 9 and 13 years, respectively. Of those who did not have protective antibody titers, 61% (33 of 54) and 67% (8 of 12), respectively, responded to a booster dose. In children of HBsAg-positive mothers, 31% retained protective anti-HBs at 12 years, and 90% (9 of 10) with nonprotective titers responded to a booster. In low risk children initially receiving a recombinant vaccine, 12.5% (26 of 208) and none (0 of 36) retained protective anti-HBs titers at 5 and 7 years of age, respectively. Of those who did not have protective titers, 90% (120 of 134) and 91% (32 of 35), respectively, responded to a booster.
  
  
  CONCLUSIONS
  Anti-HBs disappeared by 5 years of age in most children who were vaccinated with hepatitis B vaccine from birth. Although most children showed immunologic memory, one-third failed to demonstrate an anamnestic response to a booster dose. Additional long term studies of low risk infants are needed to determine duration of protection and the necessity for or timing of booster doses.
authors.affiliation: Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA.
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Petersen
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Bulkow
authors.forename: Brian J
authors.initials: BJ
authors.lastname: McMahon
authors.forename: Carolyn
authors.initials: C
authors.lastname: Zanis
authors.forename: Marilyn
authors.initials: M
authors.lastname: Getty
authors.forename: Helen
authors.initials: H
authors.lastname: Peters
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Parkinson
mesh_terms: D000413:Alaska; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008137:Longitudinal Studies; D008297:Male; D012307:Risk Factors; D013997:Time Factors
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines